Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.34 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.34 |
| ▸ | FNTA | P49354 | 3/20 | 0.33 |
| ▸ | FNTB | P49356 | 3/20 | 0.33 |
| ▸ | PTGES | O14684 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.33 |
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4291529 | 0.86 | FNTA (0.44) | ALKFNTAFNTB | |
| SCHEMBL6164984 | 0.85 | BRD4 (0.44) | BRD4CREBBPFNTAFNTBNPC1 | |
| SCHEMBL5722582 | 0.83 | NPC1 (0.37) | BRD4CREBBPFNTAFNTBNPC1 | |
| SCHEMBL5722543 | 0.77 | FNTA (0.46) | FNTAFNTBRORC | |
| SCHEMBL2495670 | 0.75 | MAPT (0.36) | ALDH1A1LMNAHPGDALKFNTA | |
| SCHEMBL27537216 | 0.75 | ALK (0.33) | ALKPTGESALOX5 | |
| SCHEMBL5722590 | 0.74 | FNTA (0.41) | ALDH1A1FNTAFNTB | |
| SCHEMBL4301651 | 0.74 | FNTA (0.36) | ALKFNTAFNTB | |
| SCHEMBL12590536 | 0.74 | FNTA (0.42) | BRD4CREBBPFNTAFNTB | |
| SCHEMBL11947178 | 0.73 | FNTA (0.43) | FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1107963-B1 | ALKYNYL-SUBSTITUTED QUINOLIN-2-ONE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PROD INC (US) | 2006-03-22 | — | — | EP | claimed |
| US-20020128287-A1 | Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents | LYSSIKATOS JOSEPH P (US) | 2002-09-12 | — | — | US | claimed |
| EP-1107963-A1 | ALKYNYL-SUBSTITUTED QUINOLIN-2-ONE DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Products Inc. (US) | 2001-06-20 | — | — | EP | claimed |
| US-6150377-A | Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents | PFIZER INC. (US) | 2000-11-21 | — | — | US | claimed |
| WO-2000012499-A1 | ALKYNYL-SUBSTITUTED QUINOLIN-2-ONE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2000-03-09 | — | — | WO | claimed |
| US-8232402-B2 | Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications | LINK MEDICINE CORPORATION (US) | 2012-07-31 | — | — | US | disclosed |
| WO-2009151683-A2 | QUINOLINONE FARNESYL TRANSFERASE INHIBITORS FOR THE TREATMENT OF SYNUCLEINOPATHIES AND OTHER INDICATIONS | LINK MEDICINE CORPORATION (US) | 2009-12-17 | — | — | WO | disclosed |
| US-20090253655-A1 | QUINOLINONE FARNESYL TRANSFERASE INHIBITORS FOR THE TREATMENT OF SYNUCLEINOPATHIES AND OTHER INDICATIONS | ASTRAZENECA AB (SE) | 2009-10-08 | — | — | US | disclosed |
| EP-1107963-B1 | ALKYNYL-SUBSTITUTED QUINOLIN-2-ONE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PROD INC (US) | 2006-03-22 | — | — | EP | disclosed |
| US-6579887-B2 | Effective in inhibiting farnesyl protein transferase; also useful in treating benign proliferative disease. | PFIZER INC | 2003-06-17 | — | — | US | disclosed |
| US-20020128287-A1 | Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents | LYSSIKATOS JOSEPH P (US) | 2002-09-12 | — | — | US | disclosed |
| US-6294552-B1 | TREATMENT OF HYPERPROLIFERATIVE DISORDERS, SUCH AS CANCER, IN MAMMALS. THE INVENTION ALSO RELATES TO METHODS OF INHIBITING ABNORMAL CELL GROWTH, INCLUDING CANCER, IN A MAMMAL BY ADMINISTERING THE COMPOUNDS OF FORMULA 1 TO A MAMMAL REQUIRING | PFIZER INC. | 2001-09-25 | — | — | US | disclosed |
| US-6150377-A | Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents | PFIZER INC. (US) | 2000-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253655-A1 | QUINOLINONE FARNESYL TRANSFERASE INHIBITORS FOR THE TREATMENT OF SYNUCLEINOPATHIES AND OTHER INDICATIONS | PANK1, PANK3, PANK2 | ALDH1A1 2151/4885LMNA 1232/4885HPGD 1359/4885 |
| US-20020128287-A1 | Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents | CCNA1, NRAS, CCNT1 | ALDH1A1 202/4885LMNA 928/4885HPGD 1590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.